Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01508728
Other study ID # 2011-A00821-40
Secondary ID 2011-A00821-40
Status Terminated
Phase Phase 2
First received January 3, 2012
Last updated September 24, 2014
Start date March 2012
Est. completion date September 2013

Study information

Verified date September 2014
Source Thuasne
Contact n/a
Is FDA regulated No
Health authority France: Agence Française de Sécurité SAnitaire des Produits de Santé
Study type Interventional

Clinical Trial Summary

Ortheses are commonly used for the repair of damage to the musculoskeletal system. However, immobility, by itself, causes serious side effects that require long and costly rehabilitation. The Sensory Feedback Ortheses allow to artificially maintain the proprioceptive and tactile flow in order to maintain the activity of their host brain areas and thus reduce significantly the usual therapy duration. The clinical study Orthosens will evaluate the efficacy and safety of the Sensory Feedback Ortheses.


Recruitment information / eligibility

Status Terminated
Enrollment 104
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients agreeing to participate in the study and who signed informed consent.

- Indication of bracing immobilization for 6 weeks following a unoperated severe sprain of the knee with partial or total rupture of the anterior cruciate ligament and a peripheral injury, medial or lateral collateral ligament, with or without meniscal lesion.

- MRI scan confirming the nature of the lesion to be provided

during the inclusion visit.

- Patients whose knee is immobilized for 7 to 15 days in Zimmer-like splint.

- Patients aged from 18 to 65.

- Patients agreeing to choose their physiotherapist from a list provided by the investigators.

- Patient (s) with insurance coverage.

Exclusion Criteria:

- Patients with a bucket handle meniscus tear.

- Patients with a pentad injury.

- Patients with osteochondral fragments.

- Patients with a knee fracture apart from "Segond fracture" and "bone bruise".

- Patients who underwent ligament surgery for the concerned knee.

- Patients with a bone lesion which may interfere with the knee joint(distal femur, proximal tibia, patella).

- Patients with any history of rupture of the central pivot (anterior cruciate ligament and posterior cruciate ligament), of lateral ligament planes rupture (medial collateral ligament and lateral collateral) or lateral planes ligament injury without rupture, dating from less than 1 year.

- Patients whose sprain results from an accident at work.

- Patients with an inability / unwillingness to follow protocol requirements.

- Patients for whom there would be no suitable brace size in the Thuasne range.

- Patients participating in another clinical study or who have tested an experimental drug within 30 days prior to study entry. - Patients with another disease which, according to the investigator, may interfere with the results or the conduct of the trial and thus justify their non-inclusion in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
ORTHOSENS orthosis
with active vibration
ORTHOSENS orthosis
with placebo vibration

Locations

Country Name City State
France Clinique Axium Aix en Provence
France Hôpital Sainte-Marguerite Marseille
France Institut de Chirurgie Orthopédique et Sportive Marseille

Sponsors (1)

Lead Sponsor Collaborator
Thuasne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Period of time required to recover a normal knee range of motion No
Secondary Period of time required to recover a normal knee range of motion with a passive mobilization The day of inclusion, then 3 times per week during 12 weeks (except at weeks 8 and 12: 4 measurements) No
Secondary Pain according to Visual Analogic Scale The day of inclusion, then 3 times per week during 12 weeks (except at weeks 8 and 12: 4 measurements) Yes
Secondary Safety according to adverse event records At any time during subject participation (12 weeks) Yes
Secondary Psychological state according to the Incredibly Short Profile of Mood States 3 times per week from week 1 to week 12 Yes
Secondary Knee functional state according to IKDC, KOOS and KOOS-PS scores The Day of inclusion, then 3 times per week during 12 weeks (except at weeks 8 and 12: 4 measurements) No
See also
  Status Clinical Trial Phase
Completed NCT00765700 - Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury Phase 3
Recruiting NCT02285868 - ATI Evidence-based Guide Investigating Clinical Services
Withdrawn NCT00954785 - Etoricoxib in Acute Ankle Ligament Sprains Phase 4
Completed NCT02916940 - Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers. Phase 2
Completed NCT00351104 - Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain Phase 3
Completed NCT00671320 - A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle Phase 4
Not yet recruiting NCT02346786 - Epidemiology of Incidents and Accidents in Sport. Influence of Moisture. Phase 3
Completed NCT00601471 - Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability N/A
Withdrawn NCT01223053 - Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury Phase 3